PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and […]
Fiscal 2024 First Quarter Financial Highlights: Consolidated sales of $450.0 million, compared to $449.2 million a year ago Industrial Technologies […]